天津中合基因科技有限公司(中合基因)于2022年成立，是國內(nèi)首家以第三代生物酶促基因合成技術(shù)及裝備開發(fā)、生產(chǎn)、銷售為核心的企業(yè)。公司致力于成為合成生物學(xué)底層核心裝備的開創(chuàng)者、全球領(lǐng)先的長鏈基因生物合成儀供應(yīng)商。中合基因以“酶促DNA合成技術(shù)”為基礎(chǔ)，現(xiàn)已成功研制第一代oligo生物合成儀原理樣機(jī)、Kb級基因拼接儀原理樣機(jī)，相關(guān)技術(shù)已獲3項(xiàng)專利認(rèn)證、5項(xiàng)專利受理審查。公司以合成基因，改造世界為愿景，打造桌面式一體化Kb級基因合成儀，開拓新型市場應(yīng)用模式，廣泛運(yùn)用于醫(yī)療診斷、藥物研發(fā)、基礎(chǔ)科研服務(wù)等領(lǐng)域。

Tianjin Zhonghe Gene Technology Co., Ltd. (Zhonghe Gene) was established in 2022 and is the first enterprise in China with the development, production and sales of third-generation biological enzymatic gene synthesis technology and equipment as the core. The company is committed to becoming the pioneer of the underlying core equipment of synthetic biology and the world's leading supplier of long-chain gene biosynthesis instruments. Based on "enzymatic DNA synthesis technology", Zhonghe Gene has successfully developed the principle prototype of the first-generation oligo biosynthesizer and the principle prototype of Kb-level gene splicing instrument, and the related technology has obtained 3 patent certifications and 5 patent acceptance and examination. With the vision of synthesizing genes and transforming the world, the company creates a desktop integrated Kb gene synthesizer, develops new market application models, and is widely used in medical diagnosis, drug research and development, basic scientific research services and other fields.